Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
PMID: 39571587
Source: Lancet Gastroenterol Hepatol
Publication date:
2025-07-24
Year:
2025
Abstract
NULL